661 related articles for article (PubMed ID: 25893302)
21. The merlin interacting proteins reveal multiple targets for NF2 therapy.
Scoles DR
Biochim Biophys Acta; 2008 Jan; 1785(1):32-54. PubMed ID: 17980164
[TBL] [Abstract][Full Text] [Related]
22. Multistep phosphorylation by oncogenic kinases enhances the degradation of the NF2 tumor suppressor merlin.
Laulajainen M; Muranen T; Nyman TA; Carpén O; Grönholm M
Neoplasia; 2011 Jul; 13(7):643-52. PubMed ID: 21750658
[TBL] [Abstract][Full Text] [Related]
23. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
[TBL] [Abstract][Full Text] [Related]
24. VprBP targets Merlin to the Roc1-Cul4A-DDB1 E3 ligase complex for degradation.
Huang J; Chen J
Oncogene; 2008 Jul; 27(29):4056-64. PubMed ID: 18332868
[TBL] [Abstract][Full Text] [Related]
25. Merlin is a negative regulator of human melanoma growth.
Murray LB; Lau YK; Yu Q
PLoS One; 2012; 7(8):e43295. PubMed ID: 22912849
[TBL] [Abstract][Full Text] [Related]
26. Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function.
Kley N; Whaley J; Seizinger BR
Glia; 1995 Nov; 15(3):297-307. PubMed ID: 8586465
[TBL] [Abstract][Full Text] [Related]
27. Calpain-dependent proteolysis of NF2 protein: involvement in schwannomas and meningiomas.
Kimura Y; Saya H; Nakao M
Neuropathology; 2000 Sep; 20(3):153-60. PubMed ID: 11132929
[TBL] [Abstract][Full Text] [Related]
28. Functional analysis of neurofibromatosis 2 (NF2) missense mutations.
Gutmann DH; Hirbe AC; Haipek CA
Hum Mol Genet; 2001 Jul; 10(14):1519-29. PubMed ID: 11448944
[TBL] [Abstract][Full Text] [Related]
29. p21-activated kinase links Rac/Cdc42 signaling to merlin.
Xiao GH; Beeser A; Chernoff J; Testa JR
J Biol Chem; 2002 Jan; 277(2):883-6. PubMed ID: 11719502
[TBL] [Abstract][Full Text] [Related]
30. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
James MF; Han S; Polizzano C; Plotkin SR; Manning BD; Stemmer-Rachamimov AO; Gusella JF; Ramesh V
Mol Cell Biol; 2009 Aug; 29(15):4250-61. PubMed ID: 19451225
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin.
Bai Y; Liu YJ; Wang H; Xu Y; Stamenkovic I; Yu Q
Oncogene; 2007 Feb; 26(6):836-50. PubMed ID: 16953231
[TBL] [Abstract][Full Text] [Related]
32. The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas.
Kimura Y; Koga H; Araki N; Mugita N; Fujita N; Takeshima H; Nishi T; Yamashima T; Saido TC; Yamasaki T; Moritake K; Saya H; Nakao M
Nat Med; 1998 Aug; 4(8):915-22. PubMed ID: 9701243
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical detection of schwannomin and neurofibromin in vestibular schwannomas, ependymomas and meningiomas.
Huynh DP; Mautner V; Baser ME; Stavrou D; Pulst SM
J Neuropathol Exp Neurol; 1997 Apr; 56(4):382-90. PubMed ID: 9100669
[TBL] [Abstract][Full Text] [Related]
34. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions.
Lallemand D; Curto M; Saotome I; Giovannini M; McClatchey AI
Genes Dev; 2003 May; 17(9):1090-100. PubMed ID: 12695331
[TBL] [Abstract][Full Text] [Related]
35. Loss of PTPRJ/DEP-1 enhances NF2/Merlin-dependent meningioma development.
Waldt N; Scharnetzki D; Kesseler C; Kirches E; Stroscher N; Böhmer FD; Mawrin C
J Neurol Sci; 2020 Jan; 408():116553. PubMed ID: 31715329
[TBL] [Abstract][Full Text] [Related]
36. Deletion of
Gerardo-Ramírez M; Giam V; Becker D; Groth M; Hartmann N; Morrison H; May-Simera HL; Radsak MP; Marquardt JU; Galle PR; Herrlich P; Straub BK; Hartmann M
Cells; 2023 Apr; 12(9):. PubMed ID: 37174657
[TBL] [Abstract][Full Text] [Related]
37. Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms.
Ruggieri M; Praticò AD; Evans DG
Semin Pediatr Neurol; 2015 Dec; 22(4):240-58. PubMed ID: 26706012
[TBL] [Abstract][Full Text] [Related]
38. Functional inactivation of NF2/merlin in human mesothelioma.
Thurneysen C; Opitz I; Kurtz S; Weder W; Stahel RA; Felley-Bosco E
Lung Cancer; 2009 May; 64(2):140-7. PubMed ID: 18835652
[TBL] [Abstract][Full Text] [Related]
39. The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells.
Bashour AM; Meng JJ; Ip W; MacCollin M; Ratner N
Mol Cell Biol; 2002 Feb; 22(4):1150-7. PubMed ID: 11809806
[TBL] [Abstract][Full Text] [Related]
40. Activation of the tumor suppressor merlin modulates its interaction with lipid rafts.
Stickney JT; Bacon WC; Rojas M; Ratner N; Ip W
Cancer Res; 2004 Apr; 64(8):2717-24. PubMed ID: 15087385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
